---
title: "BioNTech's next act has nothing to do with COVID. Here's the $500 billion market some investors are ignoring"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293678105.md"
description: "Could it become as successful in this niche as it was in the coronavirus vaccine market?"
datetime: "2026-07-23T23:41:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293678105.md)
  - [en](https://longbridge.com/en/news/293678105.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293678105.md)
generator: "portal-rs"
---

# BioNTech's next act has nothing to do with COVID. Here's the $500 billion market some investors are ignoring

Could it become as successful in this niche as it was in the coronavirus vaccine market?

### Related Stocks

- [BNTX.US](https://longbridge.com/en/quote/BNTX.US.md)

## Related News & Research

- [BioNTech to terminate mid-stage trial of mRNA cancer vaccine](https://longbridge.com/en/news/297334714.md)
- [BioNTech Kills a Cancer Trial Roche Helped Build](https://longbridge.com/en/news/297359309.md)
- [BioNTech lowers 2026 sales outlook as COVID vaccine demand softens](https://longbridge.com/en/news/294810048.md)
- [BioNTech says Sobi's Oelkers will replace Sahin as CEO](https://longbridge.com/en/news/294669487.md)
- [Founder Led Stocks With Insider Alignment Worth Watching](https://longbridge.com/en/news/296681419.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**